Xavier Jais

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4361203/publications.pdf

Version: 2024-02-01

146 papers	16,810 citations	22153 59 h-index	15732 125 g-index
151 all docs	151 docs citations	151 times ranked	9121 citing authors

#	Article	IF	Citations
1	External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. European Respiratory Journal, 2022, 59, 2102419.	6.7	83
2	Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome. ERJ Open Research, 2022, 8, 00479-2021.	2.6	16
3	Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers. Pulmonary Circulation, 2022, 12, e12023.	1.7	2
4	Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. Frontiers in Medicine, 2022, 9, 851935.	2.6	4
5	Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience. Annals of Cardiothoracic Surgery, 2022, 11, 143-150.	1.7	6
6	Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation. Journal of Heart and Lung Transplantation, 2022, 41, 1285-1293.	0.6	6
7	Preoperative C-reactive protein predicts early postoperative outcomes after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1532-1542.e5.	0.8	7
8	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. European Respiratory Journal, 2021, 57, 2002208.	6.7	12
9	Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. Chest, 2021, 159, 1197-1207.	0.8	14
10	Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La PiÃ¨ce de RÃ©sistance?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 524-525.	5.6	1
11	Reversible pulmonary hypertension associated with multivisceral Whipple's disease. European Respiratory Journal, 2021, 57, 2003132.	6.7	3
12	Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. European Respiratory Journal, 2021, 58, 2100116.	6.7	41
13	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 842-854.	5.6	94
14	Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. European Respiratory Journal, 2021, 58, 2100466.	6.7	7
15	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2021, 41, 1549-1562.	3.8	3
16	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. American Journal of Transplantation, 2021, 21, 3388-3400.	4.7	3
17	Association between Leflunomide and Pulmonary Hypertension. Annals of the American Thoracic Society, 2021, 18, 1306-1315.	3.2	8
18	Pulmonary hypertension associated with busulfan. Pulmonary Circulation, 2021, 11, 1-12.	1.7	3

#	Article	IF	Citations
19	Serum and pulmonary uric acid in pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000332.	6.7	28
20	ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002828.	6.7	287
21	Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. European Respiratory Journal, 2021, 58, 2004229.	6.7	50
22	Reply to: Jin et al. and Sun et al.. American Journal of Respiratory and Critical Care Medicine, 2021, , .	5.6	0
23	Sex and gender in pulmonary arterial hypertension. European Respiratory Review, 2021, 30, 200330.	7.1	31
24	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. European Respiratory Journal, 2020, 55, 1802108.	6.7	24
25	Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. British Journal of Anaesthesia, 2020, 125, e466-e468.	3.4	5
26	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. European Respiratory Journal, 2020, 56, 2001875.	6.7	90
27	Pulmonary Hypertension Complicating Pulmonary Artery Involvement in Pseudoxanthoma Elasticum. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e90-e91.	5.6	1
28	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 843-852.	5.6	12
29	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. European Respiratory Journal, 2020, 56, 2000279.	6.7	28
30	Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation. European Respiratory Journal, 2020, 55, 1902340.	6.7	40
31	Portopulmonary hypertension in the current era of pulmonary hypertension management. Journal of Hepatology, 2020, 73, 130-139.	3.7	78
32	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. Archivos De Bronconeumologia, 2020, 56, 578-585.	0.8	10
33	Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. International Journal of Clinical Pharmacy, 2020, 42, 1128-1138.	2.1	4
34	Screening for pulmonary arterial hypertension in systemic sclerosis. European Respiratory Review, 2019, 28, 190023.	7.1	59
35	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 833-842.	0.6	57
36	Chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801915.	6.7	607

#	Article	IF	Citations
37	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. Respiration, 2018, 95, 244-250.	2.6	17
38	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. Lung, 2018, 196, 157-164.	3.3	42
39	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2018, 37, 647-655.	0.6	50
40	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 693-704.	1.6	155
41	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. Chest, 2018, 153, 143-151.	0.8	68
42	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800678.	6.7	60
43	Pulmonary hypertension associated with neurofibromatosis type 1. European Respiratory Review, 2018, 27, 180053.	7.1	25
44	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS ONE, 2018, 13, e0197112.	2.5	47
45	Factors predicting outcome after pulmonary endarterectomy. PLoS ONE, 2018, 13, e0198198.	2.5	29
46	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. Chest, 2018, 154, 872-881.	0.8	43
47	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. Chest, 2018, 154, 882-892.	0.8	10
48	Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. Journal of Heart and Lung Transplantation, 2018, 37, 1102-1110.	0.6	20
49	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. International Journal of Clinical Pharmacy, 2018, 40, 790-794.	2.1	5
50	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respiratory Medicine,the, 2017, 5, 125-134.	10.7	123
51	Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. Archives of Cardiovascular Diseases, 2017, 110, 303-316.	1.6	37
52	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. Annals of Thoracic Surgery, 2017, 104, 404-411.	1.3	29
53	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2017, 36, 1234-1242.	0.6	37
54	Longâ€term outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology, 2017, 65, 1683-1692.	7.3	68

#	Article	IF	Citations
55	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respiratory Medicine,the, 2017, 5, 785-794.	10.7	201
56	Are indexed values better for defining exercise pulmonary hypertension?. European Respiratory Journal, 2017, 50, 1700240.	6.7	4
57	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. European Respiratory Journal, 2017, 50, 1700217.	6.7	89
58	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1700889.	6.7	527
59	Acute decompensated pulmonary hypertension. European Respiratory Review, 2017, 26, 170092.	7.1	48
60	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. Journal of Cardiac Failure, 2017, 23, 29-35.	1.7	25
61	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. Journal of Heart and Lung Transplantation, 2017, 36, 386-398.	0.6	15
62	Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. Chest, 2016, 150, 256-258.	0.8	12
63	Response to Letter Regarding Article, â€œMitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Modelâ€• Circulation, 2016, 133, e592-3.	1.6	4
64	BMPR2mutation status influences bronchial vascular changes in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1668-1681.	6.7	68
65	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. European Respiratory Journal, 2016, 48, 1517-1519.	6.7	44
66	Pulmonary veno-occlusive disease. European Respiratory Journal, 2016, 47, 1518-1534.	6.7	289
67	Initial dual oral combination therapy in pulmonary arterial hypertension. European Respiratory Journal, 2016, 47, 1727-1736.	6.7	124
68	Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 647-656.	0.6	10
69	Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure. European Respiratory Journal, 2016, 48, 254-257.	6.7	31
70	Extracorporeal Life Support After Pulmonary Endarterectomy as a Bridge to Recovery or Transplantation: Lessons From 31 Consecutive Patients. Annals of Thoracic Surgery, 2016, 102, 260-268.	1.3	27
71	Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension. Annals of the American Thoracic Society, 2016, 13, S248-S254.	3.2	15
72	Resting pulmonary artery pressure of 21â€“24â€…mmHg predicts abnormal exercise haemodynamics. European Respiratory Journal, 2016, 47, 1436-1444.	6.7	44

#	Article	IF	Citations
73	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. Chest, 2016, 149, 353-361.	0.8	55
74	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2016, 133, 859-871.	1.6	506
75	A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica. European Respiratory Review, 2016, 25, 93-96.	7.1	7
76	Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. Drug Safety, 2016, 39, 287-294.	3.2	35
77	Genetic counselling in a national referral centre for pulmonary hypertension. European Respiratory Journal, 2016, 47, 541-552.	6.7	87
78	FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. International Journal of Cardiology, 2016, 202, 52-58.	1.7	37
79	Characteristics of Pulmonary Arterial Hypertension in Affected Carriers of a Mutation Located in the Cytoplasmic Tail of Bone Morphogenetic Protein Receptor Type 2. Chest, 2015, 147, 1385-1394.	0.8	33
80	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. Medicine (United States), 2015, 94, e1800.	1.0	46
81	Chronic thromboembolic pulmonary hypertension. Presse Medicale, 2015, 44, e409-e416.	1.9	26
82	Response to Letter Regarding Article, â€œAdvances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertensionâ€• Circulation, 2015, 132, e154.	1.6	3
83	Chemotherapy-Induced Pulmonary Hypertension. American Journal of Pathology, 2015, 185, 356-371.	3.8	149
84	Usefulness of Cardiovascular Magnetic Resonance IndicesÂto Rule In or Rule Out Precapillary Pulmonary Hypertension. Canadian Journal of Cardiology, 2015, 31, 1469-1476.	1.7	10
85	Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension. International Journal of Cardiology, 2015, 184, 763-765.	1.7	3
86	Atypical Vasculitis Mimicking Chronic Thromboembolic Pulmonary Hypertension. American Journal of Medicine, 2015, 128, e47-e49.	1.5	5
87	Mitomycin-Induced Pulmonary Veno-Occlusive Disease. Circulation, 2015, 132, 834-847.	1.6	103
88	Criteria for diagnosis of exercise pulmonary hypertension. European Respiratory Journal, 2015, 46, 728-737.	6.7	213
89	New pharmacotherapy options for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2015, 16, 2113-2131.	1.8	20
90	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. European Respiratory Journal, 2015, 46, 1721-1731.	6.7	80

#	Article	IF	Citations
91	Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2015, 15, 13-26.	2.2	27
92	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. European Respiratory Journal, 2014, 44, 1069-1072.	6.7	43
93	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2014, 43, 1691-1697.	6.7	319
94	Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension. Circulation, 2014, 130, 2189-2208.	1.6	278
95	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. European Respiratory Journal, 2014, 44, 1275-1288.	6.7	201
96	Pulmonary arterial hypertension in patients treated with interferon. European Respiratory Journal, 2014, 44, 1627-1634.	6.7	80
97	Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy. European Respiratory Review, 2014, 23, 260-263.	7.1	3
98	Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191.		171
99	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry. International Journal of Cardiology, 2014, 172, 561-567.	1.7	28
100	The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2014, 8, 84-92.	2.6	7
101	Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases, 2013, 8, 97.	2.7	226
102	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. European Respiratory Journal, 2013, 41, 96-103.	6.7	92
103	Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction. Respiration, 2013, 85, 471-477.	2.6	20
104	Birth Control and Pregnancy Management in Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 681-688.	2.1	39
105	Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. European Respiratory Journal, 2013, 41, 1302-1307.	6.7	131
106	Left Ventricular Ejection Time in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension. Chest, 2013, 144, 1512-1520.	0.8	26
107	Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. European Respiratory Journal, 2012, 40, 630-640.	6.7	80
108	Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. European Respiratory Journal, 2012, 40, 881-885.	6.7	221

#	Article	IF	Citations
109	Pulmonary hypertension associated with benfluorex exposure. European Respiratory Journal, 2012, 40, 1164-1172.	6.7	75
110	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. European Respiratory Journal, 2012, 40, 75-83.	6.7	53
111	EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism: Figure 1â€“. European Respiratory Journal, 2012, 39, 1549-1550.	6.7	13
112	Mediastinal Fibrosis Mimicking Proximal Chronic Thromboembolic Disease. Circulation, 2012, 125, 2045-2047.	1.6	5
113	Potts Shunt in Children With Idiopathic Pulmonary Arterial Hypertension: Long-Term Results. Annals of Thoracic Surgery, 2012, 94, 817-824.	1.3	116
114	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. Journal of Heart and Lung Transplantation, 2012, 31, 150-158.	0.6	91
115	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation, 2012, 125, 2128-2137.	1.6	548
116	Pulmonary veno-occlusive disease: The bÃªte noire of pulmonary hypertension in connective tissue diseases?. Presse Medicale, 2011, 40, e87-e100.	1.9	25
117	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2011, 12, 1585-1596.	1.8	23
118	Pulmonary Hypertension in Patients With Neurofibromatosis Type I. Medicine (United States), 2011, 90, 201-211.	1.0	60
119	Treatment of pulmonary arterial hypertension with targeted therapies. Nature Reviews Cardiology, 2011, 8, 526-538.	13.7	125
120	Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Circulation, 2011, 124, 1973-1981.	1.6	860
121	HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. Aids, 2010, 24, 67-75.	2.2	149
122	Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis. Chest, 2010, 137, 1297-1303.	0.8	46
123	Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. European Heart Journal, 2010, 31, 1898-1907.	2.2	218
124	Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 (ALK1) Mutation. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 851-861.	5.6	259
125	Pulmonary veno-occlusive disease: Recent progress and current challenges. Respiratory Medicine, 2010, 104, S23-S32.	2.9	94
126	Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. Circulation, 2010, 122, 156-163.	1.6	1,264

#	Article	IF	Citations
127	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Advances in Therapy, 2009, 26, 813-825.	2.9	96
128	Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTUREâ€1 study. British Journal of Clinical Pharmacology, 2009, 68, 948-955.	2.4	105
129	Immunosuppressive therapy in lupusâ€•and mixed connective tissue diseaseâ€“associated pulmonary arterial hypertension: A retrospective analysis of twentyâ€three cases. Arthritis and Rheumatism, 2008, 58, 521-531.	6.7	321
130	Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology, 2008, 52, 2127-2134.	2.8	506
131	Review: Therapeutic advances in pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2008, 2, 249-265.	2.6	33
132	Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1377-1383.	5.6	269
133	Portopulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 637-643.	5.6	220
134	Pulmonary Veno-Occlusive Disease. Medicine (United States), 2008, 87, 220-233.	1.0	295
135	Pulmonary Arterial Hypertension: A Rare Complication of Primary SjÃ¶gren Syndrome. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	160
136	Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2007, 49, 1-5.	1.9	77
137	Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of Heart and Lung Transplantation, 2007, 26, 357-362.	0.6	126
138	Deleterious Effects of Î²-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension. Gastroenterology, 2006, 130, 120-126.	1.3	277
139	Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers. Journal of the American College of Cardiology, 2006, 48, 2546-2552.	2.8	498
140	Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension. Chest, 2006, 130, 182-189.	0.8	316
141	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. European Heart Journal, 2006, 27, 589-595.	2.2	272
142	Clinical Challenges in Pulmonary Hypertension. Chest, 2005, 128, 622S-628S.	0.8	23
143	Severe Pulmonary Hypertension during Pregnancy. Anesthesiology, 2005, 102, 1133-1137.	2.5	483
144	Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation, 2005, 111, 3105-3111.	1.6	1,040

#	Article	IF	Citations
145	An Extreme Consequence of Splenectomy in Dehydrated Hereditary Stomatocytosis: Gradual Thromboâ€embolic Pulmonary Hypertension and Lungâ€“Heart Transplantation. Hemoglobin, 2003, 27, 139-147.	0.8	59
146	Right heart failure. , 0, , 32-47.		0